KUNMING LONGJIN PHARMACEUTICAL CO., LTD.

Kunming Longjin Pharmaceutical Co., Ltd.

002750

CNE1000021X8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 26/06/2024 am IST			5-day change	1st Jan Change
1.61 ^CNY	-2.42%		-16.58%	-83.90%

29/04	Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/04	Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Kunming Longjin Pharmaceutical Co., Ltd. Elects Long Yungang as an Independent Director

July 10, 2018 at 09:04 pm IST

Kunming Longjin Pharmaceutical Co., Ltd. announced that at the extra ordinary general meeting Long Yungang was elected as an independent director.

Latest news about Kunming Longjin Pharmaceutical Co., Ltd.

Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Kunming Longjin Pharmaceutical Co., Ltd. Approves Board Elections	05/01	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/22/29	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	29/22/29	CI
Kunming Longjin Pharmaceutical's Shareholder Plans to Cut 6% Stake	12/22/12	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	28/21/28	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	30/21/30	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First quarter Ended March 31, 2021	27/21/27	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	14/21/14	CI
Longjin Approves Election of Directors	05/21/05	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	28/20/28	CI
Yunnan Longjin Fantian Biological Technology Co., Ltd. announced that it has received CNY 48 million in funding from Kunming Longjin Pharmaceutical Co., Ltd.	21/20/21	CI
Yunnan Longjin Fantian Biological Technology Co., Ltd. announced that it expects to receive CNY 48 million in funding from Kunming Longjin Pharmaceutical Co., Ltd.	01/20/01	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	24/20/24	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	28/20/28	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	13/20/13	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019	23/19/23	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	25/19/25	CI

Chart Kunming Longjin Pharmaceutical Co., Ltd.

Duration

Period

Chart Kunming Longjin Pharmaceutical Co., Ltd.

More charts

Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KUNMING LONGJIN PHARMACEUTICAL CO., LTD.	-83.90%	91M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.78%	43.29B
OTSUKA HOLDINGS CO., LTD.	+27.64%	22.38B
SANDOZ GROUP AG	+19.25%	15.51B
CIPLA LIMITED	+18.68%	14.52B
ZYDUS LIFESCIENCES LIMITED	+54.64%	12.93B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.39%	6.56B
ASPEN PHARMACARE HOLDINGS LIMITED	+18.33%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B